Skip to main content
Figure 4 | Radiation Oncology

Figure 4

From: [18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes

Figure 4

Biochemical relapse free survival. The biochemical relapse free survival (BRFS) rates are shown for recurrent (n = 17; dashed line) and primary prostate cancer (n = 7; blue solid line). The 2 and 3 year BRFS rates are 83.3% and 83.3% for primary, and 82.5% and 48.9% for recurrent tumours. The median survival time for recurrent tumors is 28.3 months and not reached for primary cancers. The difference between primary and recurrent cancers is not significant (p = 0.6).

Back to article page